3+ vendors tried to enroll patients for this Myasthenia Gravis study. Only Leapcure succeeded, delivering every one of the final 8 enrollments needed to complete it.

Leapcure combines advocacy outreach, targeted digital campaigns, and localized physician networks, matched to your protocol, your sites, and your patient population.

Talk to our MG recruitment team See how it works →

Final enrollments delivered

All from Leapcure, multi-agency study

Distinct sites enrolled

Leapcure patients

96%

Patient reach rate

Final month of enrollment

30+

Active MG advocacy partners

8+ countries

Understanding Myasthenia Gravis as a Clinical Trial Indication

Myasthenia gravis affects approximately 1 in 5,000 people and presents distinct recruitment challenges. The patient population is small, geographically dispersed, and spans heterogeneous disease manifestations (AChR+, MuSK+, seronegative subtypes). MG communities rely on advocacy organizations and specialist networks for trusted information, so broad-reach digital campaigns alone don't work. Serostatus complexity also creates pre-screening requirements that generic recruitment approaches can't handle. In a completed Phase 2 MG program, Leapcure's channel mix of advocacy partnerships, localized digital campaigns, and physician network activation delivered all final enrollments where other vendors could not.

Myasthenia Gravis clinical trial patient recruitment

The Challenge

MG trial recruitment demands specificity at every stage.

A small, dispersed pool demands the right access strategy

MG affects ~1 in 5,000 people. Many are concentrated in advocacy communities, specialty neurology practices, and localized physician networks that broad campaigns don't reach.

In a completed Phase 2 MG program, Leapcure's channel mix delivered all final enrollments, outperforming every other agency on the same study.

Serostatus complexity starts before site referral

AChR+, MuSK+, and seronegative MG disqualify at different rates. Pre-screening for subtype before site assignment is non-negotiable for ensuring patients referred have a realistic path to enrollment.

Leapcure pre-screens against protocol eligibility criteria before any patient is referred to a site.

Sites receive patients who participate, not just screened leads

Most recruitment vendors identify patients who might qualify and pass them to sites. Site coordinators then handle follow-up, education, and motivation. Recruitment should end with patients who are informed and ready for official screening.

Leapcure's Patient Success Team pre-screens and educates every patient before site assignment. Sites conduct official screening; Leapcure ensures the patients who arrive are worth their time.

The right channels depend on the protocol, not just the condition

Channel mix for MG trials is shaped by protocol requirements, site geography, and patient eligibility criteria. Advocacy, digital campaigns, and localized physician networks each reach different patient segments. Over-relying on any single channel leaves patients unfound.

Leapcure deploys all three channels and adjusts the mix based on what each program needs.

Three Channels. One Optimized Strategy for Your MG Trial.

Every MG study is different. Leapcure deploys the right mix of advocacy, digital, and physician networks, and adjusts continuously based on what's working.

Activate the right channels for your protocol

Leapcure deploys three recruitment channels: advocacy community outreach (30+ MG-specific organizations across 8+ countries), targeted digital campaigns (Google, Facebook, Instagram), and localized physician and specialist networks. Channel mix is adjusted to the protocol, site locations, and patient eligibility criteria of each program.

Pre-screen and educate before site referral

Every patient is spoken with by Leapcure's Patient Success Team before being assigned to a site. We assess protocol eligibility, including serostatus, and confirm patients understand what participation involves and have expressed genuine interest. Sites conduct the official screening; Leapcure makes sure the patients who show up are informed and prepared.

Optimize in real time

Channel performance is tracked continuously. Advocacy, digital, and physician referral contributions are monitored weekly and rebalanced based on referral quality and protocol progress. In a completed Phase 2 MG program, this delivered a 96% patient reach rate in the final month.

Phase 2 MG Recruitment, Completed. Every Enrollment Delivered.

Challenge Context

Indication

Myasthenia gravis, Phase 2

Sites

10 active sites across US and Canada

Challenge

Strict serostatus eligibility requirements; high industry screen-fail rates for MG; dispersed patient population across multiple geographies

Channels Deployed

Advocacy community outreach, targeted digital campaigns (Google, Facebook, Instagram), and localized physician network activation, weighted by protocol eligibility and patient population patterns

Results & Metrics

Patients Engaged

537 patients engaged by Leapcure Patient Success Team across all channels

Pre-Screened & Educated

220 patients pre-screened for protocol eligibility and educated on the trial before site assignment. Sites received informed candidates ready for official screening.

Program Outcome

All 8 final enrollments delivered by Leapcure while 3+ other recruitment agencies were on the same study. 5 distinct sites enrolled Leapcure patients. 96% patient reach rate in the final month.

Cost Efficiency

Significantly below sponsor-reported industry benchmarks for MG. Reflects this program's specific protocol and channel mix.

Three Channels. Built for MG. Active Before Your Trial Opens.

Leapcure reaches MG patients through three channels: advocacy community outreach, targeted digital campaigns, and localized physician and specialist networks. The mix is adjusted to each trial's protocol and site geography. All three are active and established before a program begins.

Channel 1 - Advocacy Network

•30+ active MG advocacy partners across 8+ countries (US, Canada, Europe, Australia).
•Leapcure team members have in-house experience at MG advocacy organizations. Network trust is earned, not purchased.
•Mobilizable within 2 days of program launch.

Channel 2 - Targeted Digital Campaigns

•Google, Facebook, and Instagram campaigns optimized for MG-specific patient populations.
•Strike-zone targeting by geography, symptom profile, and indication-relevant interest signals.
•$111 digital acquisition cost in completed MG programs, well below industry average.

Channel 3 - Localized Physician and Specialist Networks

•Identifying localized networks of MG patients: the neurology practices, infusion centers, and community clinics where MG patients are actively managed but rarely reached by national recruitment campaigns.
•Reaches patient segments that advocacy and digital alone don't cover.

Living with Myasthenia Gravis? A Clinical Trial May Be an Option.

If you're living with myasthenia gravis, a clinical trial may give you access to investigational treatments not yet widely available. If you're interested in whether a trial could be an option, we can help you find out.

See if a trial may be right for you

Leapcure's rare disease and neuromuscular recruitment team has completed Phase 2 MG programs, delivering every final enrollment in a multi-agency study where other vendors could not. We deploy the right mix of advocacy, digital, and physician networks for your protocol, and we can mobilize within 48 hours of launch.

Talk to our MG recruitment team